DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
O'Sullivan C, Edgerly M, Velarde M. et al.
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
J Clin Endocrinol Metab 2014;
99: 1291-1297
We do not assume any responsibility for the contents of the web pages of other providers.